X-chromosome inactivation based clonality assays, first described by Fialkow and co-workers (1), have the important advantage of not relying on any specific tumor markers, and can thus potentially determine clonal derivation of cells in any informative female. These assays rely on the ability to distinguish between (i) the maternal vs. paternal X chromosome using polymorphisms and (ii) the active vs. the inactive X chromosome using either differential expression of genes or differential methylation of the active vs. inactive X. Fialkow's original approach was based on a rare coding polymorphism at the glucose-6-phosphate dehydrogenase (G6PD) locus on chromosome X, and is limited by low informativeness. An alternative strategy developed by Vogelstein et al. takes advantage of changes in methylation patterns that accompany inactivation of the X chromosome, which can be delineated with methylation sensitive restriction endonucleases such as HpaU. Informative restriction fragment length polymorphisms (RFLP) associated with the phosphoglycerate kinase (PGK) and hypoxanthine phosphoribosyl transferase (HPRT) loci, and the highly informative VNTR at the DXS255 locus have expanded informativeness to include most females. However, there has been concern that differential methylation at these loci is not a reliable marker for the state of activation of the X chromosome, or that variable methylation may occur in association with malignancy. This is well exemplified at the DXS255 locus analyzed with the M27/3 probe which is hypermethylated in a significant proportion of acute myelogenous leukemia blast populations (3). Until recently, no locus has had a coding polymorphism coupled with differential methylation sites which would allow comparison of both the expression and methylation based assays at the same locus. Such a combination would allow validation of differential methylation based assays in comparison with expression analysis at the same locus.
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The human androgen receptor assay (HUMARA) is a newly described clonality assay that takes advantage of a highly polymorphic trinucleotide repeat in the coding region of the first exon of the human androgen receptor gene (4) . The CAG repeat is closely linked to four methylation sites that have served as the basis for studying X-inactivation patterns in female carrier of XlinJced hemopathies (4) . The methylation sites are unmethylated on the active X chromosome and methylated on the inactive X chromosome. We have devised an expression assay at this locus using a reverse transcriptase (RT) PCR strategy that allows clonality determination without relying on differential methylation of X chromosomes. We have compared the expression assay with the differentia] methylation based assay in informative female patients with hematologic malignancies (4) and brain tumor (1) and found concordant results in each case. The expression clonality assay described in this report has the potential of being informative in more than 90% of females, which is a significant advance for the field. Furthermore, this expression assay allows for a unique validation of the differential methylation based assay, confirming the reliability of the methylation patterns at the human androgen receptor in this small series of patients. However, usefulness of the HUMARA expression assay may be limited by the level of expression of the androgen receptor in different tumors or tissues.
Human androgen receptor expression assay: reverse transcription
The RT-PCR assay was based on a nested primer strategy described by Baier et al. (5) . Briefly, RNA was isolated from peripheral blood mononuclear cells (4 patients) and from tumor specimen (1 patient) using the RNAzol™ (Tel-Test, Inc.) method according to manufacturer recommendations and from a brain tumor specimen (1 patient) by the method of Chirgwin (6) . Two /xg of total RNA was added to a tube containing 18 Ail of a mix of dNTP (lmMof each); RT buffer (5 x: 250 mM Tris-HCl, 40 mM MgCl 2 , 50 mM KC1 1, 5 mM dithiothreitol; pH 8.5); nested primer: 5-GGCTCCAGGCTCTGGGACGC-AACCTCT-3' (20 pmol); AMV reverse transcriptase (40 units, Boehringer Mannheim). Reverse transcription was performed at 42°C for 60 min and enzyme was inactivated at 90°C for 10 min. A mock reverse transcription lacking reverse transcriptase was performed as a control for DNA contamination. PCR amplification of the HUMARA locus: 2 /*1 of reverse transcription products were added to 23 /il of a PCR mix containing buffer (10x: 500 mM NaCl, 100 mM Tris-HCl, pH 8. At the end of amplification 12.5 /tl of formamide loading buffer (95% fonnamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) was added to each sample, and samples were denatured at 95°C for 3 min and chilled rapidly. Amplified PCR products (8-10 /tl) were electrophoresed on a 4% acrylamide-urea-formamide denaturing gel at 80 watts for 3.5 hours. The gel was dried and exposed to a phosphor screen for 24 hours, scanned on a Phosphorimager (Molecular Dynamics) and allelic ratios were quantitated with ImageQuant software.
Differential methylation based clonality assay
The HUMARA assay was carried out as previously described (4) with minor modifications. Briefly, genomic DNA was precut by mixing sample DNA (100 ng-1 /tg in 2 /tl) with HpaU (1 /tl, high concentration, 40 U//tl), Rsal (0-5 /tl, high concentration, 40 U//tl), L buffer (2 /tl, Boehringer Mannheim) and H 2 O (14.5 /tl). An auto-control was precut in the same way except that HpaU was omitted from the mix. Samples were incubated at 37°C overnight, and heat inactivated at 95°C for 10 min prior to amplification. The HUMARA locus was amplified as described above.
